Lincoln Pharmaceuticals Ltd Stock Price Today (NSE: LINCOLN)

Lincoln Pharmaceuticals Ltd

629.7516.25 (2.52%)
Market Open

Fundamental Score

...

Lincoln Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Lincoln Pharmaceuticals Ltd share price today is 629.75, down 2.52% on NSE/BSE as of 17 June 2026. Lincoln Pharmaceuticals Ltd (LINCOLN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 1.01K (Cr). The 52-week high for LINCOLN share price is 770.00 and the 52-week low is 440.00. At a P/E ratio of 12.68x, LINCOLN is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.82% and a debt-to-equity ratio of 0.00.

Lincoln Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
770.00
Low
600.15
Volume
2.7L
Change
+21.89%

Lincoln Pharmaceuticals Ltd share price chart: 21.89% return over the past month. 52-week high ₹770.00, 52-week low ₹440.00.

Lincoln Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
620.00620.00586.40590.001.79L (Cr)
632.95650.00598.40606.201.77L (Cr)
687.95697.85620.00632.955.45L (Cr)
758.15758.15758.15758.150.00 (Cr)
758.60770.00738.30758.151.24L (Cr)
715.10755.00715.10747.451.03L (Cr)
736.00747.00714.10719.1577.56K (Cr)
736.00750.20731.00734.151.39L (Cr)
710.80735.00700.10732.151.35L (Cr)
714.65714.65702.00705.2059.07K (Cr)

Lincoln Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
632.95650.00586.40590.00-6.79%
647.00770.00620.00632.95-2.17%
575.00733.00545.00645.80+12.31%
605.50651.45560.40564.95-6.70%
458.75677.00452.90631.05+37.56%
485.20505.00440.00456.45-5.93%
510.00515.00464.40483.95-5.11%
530.50542.90490.00511.95-3.50%
531.00545.00518.00529.80-0.23%
537.15565.75529.00532.20-0.92%
533.00624.40523.00538.65+1.06%
566.75581.60532.10533.45-5.88%

Returns & Performance

Poor

Return on Equity (ROE)

12.82%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

17.28%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

18.17%

Average operating profit margin over 5 years

Dividend Yield

0.36%

Annual dividend as % of current share price

Lincoln Pharmaceuticals Ltd Valuation Check

Excellent

Price to Earnings (P/E)

12.68x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

49.78%

% shares held by company founders/management

Poor

FII Holding

4.73%

% shares held by foreign institutional investors

Poor

DII Holding

0.01%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-24.12%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

1.33%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.03%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

9.47%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

9.50%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

71.86x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

214.56 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Lincoln Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of LINCOLN across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Excellent ROCE Performance (17.28%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (18.17%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 12.68 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (71.86x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹214.56 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Profit Decline Concern (-24.12%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Institutional Interest (FII+DII: 4.74%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Lincoln Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Lincoln Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
51.5/100
630
₹1014.61
12.7
Average
12.82%
Average
17.28%
Good
0.0
Excellent
9.50%
Good
10.03%
Good
0.36%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Lincoln Pharmaceuticals Ltd PE Ratio History

Historical price-to-earnings ratio for LINCOLN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202541.11₹483.9511.8x
FY 202446.58₹787.8016.9x
FY 202336.40₹609.5016.7x
FY 202234.63₹355.5510.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Lincoln Pharmaceuticals Ltd Dividend History

Annual cash dividends paid by LINCOLN — dividend yield 0.36%

Financial YearDividends Paid (₹ Cr)
FY 20253.61 Cr
FY 20243.00 Cr
FY 20233.00 Cr
FY 20223.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Lincoln Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for LINCOLN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

1.33%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-24.12%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.03%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

9.50%

Compounded annual net profit growth over 5 years

Lincoln Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for LINCOLN — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
632
▼ Price below SMA 50 — Short-term bearish
SMA 200
555
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
214K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Lincoln Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Lincoln Pharmaceuticals Ltd (LINCOLN) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Lincoln Pharmaceuticals Ltd

About LINCOLN (Lincoln Pharmaceuticals Ltd)

Lincoln Pharmaceuticals Ltd is a dynamic and forward-thinking pharmaceutical company dedicated to enhancing global health through the development, manufacturing, and distribution o...f high-quality medicines. With a strong focus on innovation and patient well-being, Lincoln Pharmaceuticals strives to address diverse medical needs across a wide spectrum of therapeutic areas. The company's state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring the safety and efficacy of its products. Committed to research and development, Lincoln Pharmaceuticals continuously explores new formulations and drug delivery systems to improve treatment outcomes and patient compliance. The company's ethical business practices, coupled with its dedication to social responsibility, solidify its position as a trusted healthcare partner. Lincoln Pharmaceuticals' comprehensive product portfolio encompasses a diverse range of therapeutic categories, catering to various medical conditions and patient populations. From essential medicines addressing common ailments to specialized treatments for chronic diseases, the company's offerings are designed to improve the quality of life for individuals worldwide. A dedicated team of medical professionals and scientists work collaboratively to develop and refine formulations, ensuring optimal therapeutic benefits. By leveraging cutting-edge technology and adhering to rigorous quality control measures, Lincoln Pharmaceuticals consistently delivers safe, effective, and affordable medicines to meet the evolving healthcare needs of the global community. Beyond its domestic operations, Lincoln Pharmaceuticals has established a robust international presence, exporting its products to numerous countries across diverse continents. This global reach reflects the company's commitment to making quality healthcare accessible to people around the world. By forging strategic partnerships and navigating complex regulatory landscapes, Lincoln Pharmaceuticals continues to expand its market presence and contribute to the advancement of healthcare in emerging and developed economies alike. The company's unwavering dedication to quality, innovation, and patient-centricity positions it as a reliable and trusted provider of pharmaceutical solutions on a global scale.

Company Details

Symbol:LINCOLN
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mahendrabhai Gulabdas Patel B.A, LLB
MD & Whole Time Director
Mr. Darshit Ashvinkumar Shah
Chief Financial Officer
Ms. Trusha Kashish Shah
Company Secretary & Compliance Officer

LINCOLN Share Price: Frequently Asked Questions

What is the current share price of Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd (LINCOLN) trades at ₹629.75 on NSE and BSE. Market cap ₹1.01K (Cr). Educational data only.

What is the P/E ratio of Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd has a P/E of 12.68x vs industry average 31.77x.

What is the Bull Run score for Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd has a Bull Run score of 51.5/100 based on 25+ financial parameters.

Does Lincoln Pharmaceuticals Ltd pay dividends?

Lincoln Pharmaceuticals Ltd has a dividend yield of 0.36%. Past dividends don't guarantee future payments.

What is the ROE of Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd has ROE of 12.82%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Lincoln Pharmaceuticals Ltd?

Lincoln Pharmaceuticals Ltd has debt-to-equity of 0.00.

Is Lincoln Pharmaceuticals Ltd a good investment?

Bull Run gives Lincoln Pharmaceuticals Ltd a score of 51.5/100. This is not investment advice — consult a SEBI-registered advisor.